Endodiag is an innovative company founded in January 2011. Endodiag is specialized in the development of non-invasive diagnosis tools for endometriosis. This complex disease affects over 10% of women and causes severe chronic pain and infertility. Today it can only be diagnosed through a surgical procedure with an average of 9 years between the onset and the diagnosis. The goal of our company is to significantly improve the lives of millions of women suffering from endometriosis through a simpler and better diagnosis of the disease.

The company relies on work performed for 20 years now by its scientific founders, Pr. Bouquet de la Joliniere, obstetric surgeon, and Pr. Gogusev, pathologist and cytogeneticist at INSERM. In 1998 their work on endometriosis was awarded the Major Prize Award at the 16th World Congress of Fertility Societies and the American Society for Reproductive Medicine in San Francisco, USA.

Endodiag proposes, through its first product EndoGram ®, to improve the accuracy of endometriosis diagnoses made from laparoscopic biopsies (sampling kit and progression score) while working on the development of an innovative in-vitro diagnostic test of the disease based on a simple blood sample. This IVD test will allow for a non-invasive detection of endometriosis. This product will have a major impact on the management of the disease and on the quality of life of patients.

Finally, Endodiag aims to help research teams (industrial or academic) working on new therapeutic strategies to fight endometriosis by proposing a drug testing service, EndoTesting ®, using its proprietary cell lines and its tissue collection (EndoBiobank ®)



Cécile Réal

Cécile Réal (1973) is a French bio medical engineer and business executive. In 2012, as president of Endodiag, she won the Cartier Women’s Initiative Award for developing tools to diagnose and treat endometriosis.

Réal, who studied bio mechanical engineering at the University of Technology of Compiègne (1991–1996) also has a master’s degree in business and technology management from Lappeenranta University of Technology in Finland. In 1999, when she was only 25, she founded and ran Bioprofile which produced orthopedic implants with pyrocarbon. She sold the company in 2007, deeming it important to allow more experienced players to bring the products to market.


While serving as chief operating officer at Ariana Pharma (2008–2010), a company specializing in biomarkers, in 2009 she founded Fluotpics which handles fluorescence imaging for cancer surgery. In 2011, she co-founded Endodiag where she is CEO.

Endodiag specializes in endometriosis which occurs when small pieces of the lining of the womb migrate to other parts of the body. The cells cause pain and can lead to infertility. It is not unusual for diagnosis to take up to nine years. The company is developing methods to improve diagnosis with tools such as EndoGram, based on biopsy, and EndoDiag, relying on a simple blood test.

View Cécile Réal’s profile on LinkedIn

[ultimate_fancytext fancytext_prefix=”Challenge: ” strings_textspeed=”35″ strings_backspeed=”0″ typewriter_loop=”off” fancytext_tag=”h1″ fancytext_strings=”‘Changing the life of 180 million women with endometriosis’” ex_class=”h1″]


We are looking for financial funding. One one hand to further develop our (tangible) solution and on the other hand validation of our solution. The reason we need financing is to expand our FTE in the domain of science, clinical and industrial development.


Also we believe it is very important to run Awareness Campaigns. E.g. create awareness for a Business Case focused on the fact that after diagnosing Endometriose costs of treatment are around 40 billion EUR / year. Prevention or informing potential patients would safe a lot of money and improve the patients well being or chance to survive.

Creative Minds

In the next few days the group of carefully selected Creative Minds will be named.


  1. How could we leverage strategic partnerships? So far this seems to work better with diagnostic companies than commercial or other partnerships in the domain of pharma or biotech.
  2. What do we need to take into account with regards to regulation / re-reimbursement?
  3. What commercial structure would be best to support expansion?